BioArctic AB (publ) (FRA:B9A)

Market Cap	2.56B +79.2%
Revenue (ttm)	104.54M -24.4%
Net Income	19.43M -76.4%
EPS	0.22 -76.4%
Shares Out	n/a
PE Ratio	131.77
Forward PE	181.83
Dividend	0.19 (0.62%)
Ex-Dividend Date	May 29, 2026

Volume	n/a
Open	28.92
Previous Close	30.04
Day's Range	28.92 - 28.92
52-Week Range	15.75 - 34.96
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 23, 2026

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B9A

Financial Performance

Financial numbers in SEK